Quantinno Capital Management LP Grows Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Quantinno Capital Management LP lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 43.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 25,909 shares of the medical research company’s stock after purchasing an additional 7,850 shares during the period. Quantinno Capital Management LP’s holdings in IQVIA were worth $5,092,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in IQVIA by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company’s stock valued at $3,956,087,000 after purchasing an additional 105,504 shares during the period. Canada Pension Plan Investment Board lifted its holdings in IQVIA by 20.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company’s stock worth $841,461,000 after buying an additional 712,958 shares during the last quarter. Geode Capital Management LLC lifted its holdings in IQVIA by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company’s stock worth $818,315,000 after buying an additional 77,981 shares during the last quarter. Invesco Ltd. lifted its holdings in IQVIA by 53.4% during the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company’s stock worth $509,012,000 after buying an additional 902,226 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in IQVIA by 2.5% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company’s stock worth $481,380,000 after buying an additional 59,426 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of recent analyst reports. Robert W. Baird decreased their price target on IQVIA from $195.00 to $161.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Truist Financial cut their target price on IQVIA from $263.00 to $216.00 and set a “buy” rating on the stock in a research report on Thursday, April 10th. JPMorgan Chase & Co. cut their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. Finally, Stifel Nicolaus cut their target price on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Eight equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $230.76.

IQVIA Stock Performance

Shares of IQV stock opened at $142.66 on Friday. The stock has a market capitalization of $24.68 billion, a PE ratio of 19.02, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a 52-week low of $135.97 and a 52-week high of $252.88. The stock’s 50-day moving average price is $159.83 and its 200 day moving average price is $185.86. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating analysts’ consensus estimates of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The company had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. During the same quarter in the previous year, the company earned $2.54 EPS. The firm’s revenue for the quarter was up 2.5% compared to the same quarter last year. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.